Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Intravenous Remicade Grows Despite Tough Times

This article was originally published in The Pink Sheet Daily

Executive Summary

Implications for anti-TNFs Humira and Enbrel, which tumbled in the first quarter, are unclear.
Advertisement

Related Content

With New Crohn's Disease Treatment, China's Hutchison MediPharma Seeks Global Co-development Partner
With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results
With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results
Amgen Ups Ante With Co-Pay Relief For Patients On TNF Blockers
Amgen Ups Ante With Co-Pay Relief For Patients On TNF Blockers

Topics

Advertisement
UsernamePublicRestriction

Register

PS069695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel